(redirected from Postmenopausal Estrogen/Progestin Intervention)
PEPIPhysics of the Earth and Planetary Interiors (est. 1968; Elsevier, BV)
PEPIPostmenopausal Estrogen/Progestin Intervention (female health)
PEPIPrivate Equity Performance Index (Thomson Financial)
PEPIPatient Experience and Public Involvement
PEPIProcessor Equipment Prime Item
PEPIPublic Education Public Involvement (community planning)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
New information from the Postmenopausal Estrogen/Progestin Intervention Trial (PEPI) suggests that HRT may also improve coronary heart disease risk factors after menopause.
Barrett-Connor and her colleagues examined data from 823 participants in the Postmenopausal Estrogen/Progestin Interventions trial.
Moreover, in the National Heart, Lung, and Blood Institute's Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, women assigned to 0.625 mg of conjugated equine estrogen plus medroxyprogesterone acetate had much greater increases in mammographic densities--a well-established marker for increased breast cancer risk--than with estrogen alone (Ann.
The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial demonstrated that MPA mitigates estrogen's beneficial effects on lipids while micronized progesterone does not.
Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study.
In the 875-patient Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, for example, the various HRT regimens that were studied resulted in an average 9% rise in cardioprotective HDL cholesterol at 3 years, Dr.
To learn more about estrogen's possible benefits and risks, the National Heart, Lung, and Blood Institute (NHLBI) and other units of the National Institutes of Health started a major clinical trial in 1987--the "Postmenopausal Estrogen/Progestin Interventions Trial," called PEPI.
Much of the best comparative data about agents used in HT has been derived from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
The recently reported Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial was a multicenter, placebo-controlled, double-blinded, randomized study designed to assess the effect of estrogen alone and estrogen/progestin combinations (including continuous-dose medroxyprogesterone) compared with placebo on cardiac risk factors such as low HDL and elevated LDL, systolic blood pressure, insulin levels, and fibrinogen levels.[10] There was no significant demonstrated effect on insulin levels or blood pressure.
The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial reported whthe following effects on high-density lipoprotein cholesterol associated with hormone therapy (HT)
One good example is the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, which is the best randomized study for which data are currently available on the use of estrogen and progestin in early postmenopausal women [JAMA.
Full browser ?